6α-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
A series of 6alpha-alkyl-substituted analogues of chenodeoxycholic acid (CDCA) were synthesized and evaluated as potential farnesoid X receptor (FXR) ligands. Among them, 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA) was shown to be a very potent and selective FXR agonist (EC(50) = 99 nM) and to be endowed with anticholeretic activity in an in vivo rat model of cholestasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A bile acid receptor (FXR) agonist has reached the market since this programme started: obeticholic acid (Ocaliva), which was discovered by GSK in collaboration with the University of Perugia51 and subsequently developed by Intercept Pharmaceuticals.”
From Unexplored therapeutic opportunities in the human genome (2018) · cites this paper as [51]
In the citing paper
“OCA is a farnesoid X receptor (FXR) agonist that is 100 times more potent than the endogenous ligand, chenodeoxycholic acid.(156)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [156]
In the citing paper
“Obeticholic acid has approximately 100 times greater potency in activating FXR than chenodeoxycholic acid. 11”
From A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis (2016) · cites this paper as [11]
In the citing paper
“Obeticholic acid is a selective farnesoid X receptor (FXR) agonist that is derived from the bile acid chenodeoxycholic acid, the endogenous FXR ligand.”
From A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis (2016) · cites this paper as [11]
In the citing paper
“OCA, a 6α-ethyl derivate of chenodeoxycholic acid, is a steroidal FXR agonist (still maintaining its BA structure) and first-in-class therapeutic FXR ligand.94”
From Novel therapeutic targets for cholestatic and fatty liver disease (2022) · cites this paper as [94]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Identification of a nuclear receptor for bile acids
Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., Hull, M. V., Lustig, K. D., Mangelsdorf, D. J., & Shan, B. (1999) · Science · doi:10.1126/science.284.5418.1362 · Cited by 2,714
Bile Acids: Natural Ligands for an Orphan Nuclear Receptor
Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., et al. (1999) · Science · doi:10.1126/science.284.5418.1365 · Cited by 2,274
Self-citationNuclear Receptors and Lipid Physiology: Opening the X-Files
Chawla, A., Repa, J. J., Evans, R. M., & Mangelsdorf, D. J. (2001) · Science · doi:10.1126/science.294.5548.1866 · Cited by 2,085
A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis
Goodwin, B., Jones, S. A., Price, R. R., Watson, M. A., McKee, D. D., Moore, L. B., Galardi, C., Wilson, J. G., Lewis, M. C., Roth, M. E., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00051-4 · Cited by 1,940
Self-citationTargeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819
Endogenous Bile Acids Are Ligands for the Nuclear Receptor FXR/BAR
Wang, H., Chen, J., Hollister, K., Sowers, L. C., & Forman, B. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80348-2 · Cited by 1,636
Combinatorial Control of Gene Expression by Nuclear Receptors and Coregulators
McKenna, N. J., & O'Malley, B. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00641-4 · Cited by 1,463
The Continuing Importance of Bile Acids in Liver and Intestinal Disease
Hofmann, A. F. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.22.2647 · Cited by 982
Modulation of Polyketide Synthase Activity by Accessory Proteins During Lovastatin Biosynthesis
Kennedy, J., Auclair, K., Kendrew, S. G., Park, C., Vederas, J. C., & Richard Hutchinson, C. (1999) · Science · doi:10.1126/science.284.5418.1368 · Cited by 654
Identification of a Chemical Tool for the Orphan Nuclear Receptor FXR
Maloney, P. R., Parks, D. J., Haffner, C. D., Fivush, A. M., Chandra, G., Plunket, K. D., Creech, K. L., Moore, L. B., Wilson, J. G., Lewis, M. C., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm0002127 · Cited by 527
Self-citation
Research works printed but not linked: 3
- Mangelsdorf D. J., 1995, Cell, 83, 850
- Forman B. M., 1995, Cell, 81, 693
- Lu T. T., 2000, Mol. Cell, 6, 515
Cited by
Items 101–200 of 793
Tølbøl, K. S., Kristiansen, M. N., Hansen, H. H., Veidal, S. S., Rigbolt, K. T., Gillum, M. P., Jelsing, J., Vrang, N., & Feigh, M. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i2.179 · Cited by 134
Natural products as modulators of the nuclear receptors and metabolic sensors LXR, FXR and RXR
Hiebl, V., Ladurner, A., Latkolik, S., & Dirsch, V. M. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.03.003 · Cited by 134
“This potent FXR agonist (EC50 of 99 nM in an FXR transactivation assay) has been and is currently investigated in several clinical trials (http://www.clinicaltrials.gov; Nevens et al., 2016; Pellicciari et al., 2002; Schaap et al., 2014).”
MethodÐanić, M., Stanimirov, B., Pavlović, N., Goločorbin-Kon, S., Al-Salami, H., Stankov, K., & Mikov, M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01382 · Cited by 133
“…only obeticholic acid (OCA, 6-ethyl-chenodeoxycholic acid, 6-ECDCA INT-747) has currently been clinically useful and approved as a potent and specific FXR agonist with 100-fold higher affinity compared to the CDCA – endogenous FXR agonist with the highest potency (Pellicciari et al., 2002).”
BackgroundSanyal, A. J., Ratziu, V., Loomba, R., Anstee, Q. M., Kowdley, K. V., Rinella, M. E., Sheikh, M. Y., Trotter, J. F., Knapple, W., Lawitz, E. J., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.014 · Cited by 137
Caussy, C., Hsu, C., Singh, S., Bassirian, S., Kolar, J., Faulkner, C., Sinha, N., Bettencourt, R., Gara, N., Valasek, M. A., et al. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15035 · Cited by 129
Harrison, S. A., Bashir, M. R., Lee, K.-J., Shim-Lopez, J., Lee, J., Wagner, B., Smith, N. D., Chen, H. C., & Lawitz, E. J. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.01.047 · Cited by 130
Farnesoid X Receptor: From Structure to Potential Clinical Applications
Pellicciari, R., Costantino, G., & Fiorucci, S. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0582221 · Cited by 130
Self-citationProgress and challenges of selective Farnesoid X Receptor modulation
Massafra, V., Pellicciari, R., Gioiello, A., & van Mil, S. W. C. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.06.009 · Cited by 141
Self-citationRatziu, V., Sanyal, A. J., Loomba, R., Rinella, M., Harrison, S., Anstee, Q. M., Goodman, Z., Bedossa, P., MacConell, L., Shringarpure, R., et al. (2019) · Contemporary Clinical Trials · doi:10.1016/j.cct.2019.06.017 · Cited by 126
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease
Romero, F. A., Jones, C. T., Xu, Y., Fenaux, M., & Halcomb, R. L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01701 · Cited by 120
FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid
Wang, K., Zhang, Y., Wang, G., Hao, H., & Wang, H. (2024) · Medicinal Research Reviews · doi:10.1002/med.21991 · Cited by 117
Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy
Purohit, T., & Cappell, M. S. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i7.926 · Cited by 138
The Pharmacology of Bile Acids and Their Receptors
Fiorucci, S., & Distrutti, E. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_238 · Cited by 124
Self-citationWu, W., Zhu, B., Peng, X., Zhou, M., Jia, D., & Gu, J. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.11.057 · Cited by 119
Current and potential treatments for primary biliary cholangitis
Shah, R. A., & Kowdley, K. V. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30343-7 · Cited by 115
Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids
Zhang, J. H., Nolan, J. D., Kennie, S. L., Johnston, I. M., Dew, T., Dixon, P. H., Williamson, C., & Walters, J. R. F. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00398.2012 · Cited by 113
Alvarez, L., Jara, P., Sánchez-Sabaté, E., Hierro, L., Larrauri, J., Díaz, M. C., Camarena, C., De la Vega, A., Frauca, E., López-Collazo, E., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh261 · Cited by 114
“Specific FXR agonists have been developed, and have been assayed in both culture systems and animal models (12,36,53,54).”
BackgroundPositive regulation of osteogenesis by bile acid through FXR
Cho, S. W., An, J. H., Park, H., Yang, J.-Y., Choi, H. J., Kim, S. W., Park, Y. J., Kim, S. Y., Yim, M., Baek, W.-Y., et al. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1961 · Cited by 113
“The positive regulation of bone formation by FXR in vivo was further validated by the increased osteoblast differentiation of mesenchymal cells by treatment with CDCA and 6‐ECDCA as a natural and semisynthetic bile acid, respectively,((24,25)) in vitro.”
BackgroundExploitation of Bile Acid Transport Systems in Prodrug Design
Sievänen, E. (2007) · Molecules · doi:10.3390/12081859 · Cited by 113
“Since bile acids are capable of downregulating their own biosynthesis, investigations of the structural changes of bile acids on the regulation of bile acid biosynthesis have been performed [48, 49].”
BackgroundRole of farnesoid X receptor and bile acids in alcoholic liver disease
Manley, S., & Ding, W. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2014.12.011 · Cited by 112
Molecular tuning of farnesoid X receptor partial agonism
Merk, D., Sreeramulu, S., Kudlinzki, D., Saxena, K., Linhard, V. L., Gande, S. L., Hiller, F., Lamers, C., Nilsson, E., Aagaard, A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10853-2 · Cited by 114
Transcriptional regulation of human UDP-glucuronosyltransferase genes
Hu, D. G., Meech, R., McKinnon, R. A., & Mackenzie, P. I. (2014) · Drug Metabolism Reviews · doi:10.3109/03602532.2014.973037 · Cited by 130
“As CDCA is a natural inducer of FXR (Pellicciari et al., 2002) and a substrate of UGT1A3, the hepatic induction of UGT1A3 by CDCA via FXR would facilitate bile acid detoxification and excretion, suggesting a role for this regulation in the”
BackgroundThe farnesoid X receptor induces very low density lipoprotein receptor gene expression
Sirvent, A., Claudel, T., Martin, G., Brozek, J., Kosykh, V., Darteil, R., Hum, D. W., Fruchart, J.-C., & Staels, B. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.04.026 · Cited by 109
Functional and Structural Features of Cholangiocytes in Health and Disease
Maroni, L., Haibo, B., Ray, D., Zhou, T., Wan, Y., Meng, F., Marzioni, M., & Alpini, G. (2015) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2015.05.005 · Cited by 107
Obeticholic Acid: First Global Approval
Markham, A., & Keam, S. J. (2016) · Drugs · doi:10.1007/s40265-016-0616-x · Cited by 117
“It is highly lipophilic, but has no intrinsic cholestatic activity [7].”
Bowlus, C. L., Pockros, P. J., Kremer, A. E., Parés, A., Forman, L. M., Drenth, J. P. H., Ryder, S. D., Terracciano, L., Jin, Y., Liberman, A., et al. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.09.050 · Cited by 105
Pellicciari, R., Sato, H., Gioiello, A., Costantino, G., Macchiarulo, A., Sadeghpour, B. M., Giorgi, G., Schoonjans, K., & Auwerx, J. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070633p · Cited by 103
Self-citationBile acid diarrhoea and FGF19: new views on diagnosis, pathogenesis and therapy
Walters, J. R. F. (2014) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2014.32 · Cited by 112
Iracheta‐Vellve, A., Calenda, C. D., Petrasek, J., Ambade, A., Kodys, K., Adorini, L., & Szabo, G. (2018) · Hepatology Communications · doi:10.1002/hep4.1256 · Cited by 103
Bile acids activated receptors in inflammatory bowel disease
Biagioli, M., Marchianò, S., Carino, A., Di Giorgio, C., Santucci, L., Distrutti, E., & Fiorucci, S. (2021) · Cells · doi:10.3390/cells10061281 · Cited by 103
Self-citationMiyazaki‐Anzai, S., Levi, M., Kratzer, A., Ting, T. C., Lewis, L., & Miyazaki, M. (2010) · Circulation Research · doi:10.1161/circresaha.109.212969 · Cited by 103
Tissue-specific function of farnesoid X receptor in liver and intestine
Zhu, Y., Li, F., & Guo, G. L. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2010.12.018 · Cited by 100
“Increasing numbers of non-bile acid modulators that activate FXR with high potency have been developed, including GW4064 [28], 6α-ethyl-CDCA [29], fexaramine [30], methyl cholate, methyl deoxycholate, 5β-cholanic acid, 5β-cholanic acid-7α,12α-diol, NIHS700, marchantin A and marchantin E, and MFA-1 [31,32].”
Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH)
Fiorucci, S., Biagioli, M., Sepe, V., Zampella, A., & Distrutti, E. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1763302 · Cited by 104
“development of semisynthetic derivatives of natural bile acids, we have reported in 2002 the generation of a semisynthetic derivative of CDCA, the 6-ethyl-CDCA [39], later renamed INT747 [62] which has been then christened as obeticholic acid by Intercept Pharmaceuticals in 2009.”
BackgroundSelf-citationHambruch, E., Miyazaki‐Anzai, S., Hahn, U. K., Matysik, S., Boettcher, A., Perović‐Ottstadt, S., Schlüter, T., Kinzel, O. D., Krol, H. D., Deuschle, U., et al. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.196519 · Cited by 104
“…acid (PX20350) were synthesized according to published synthesis protocols (Maloney et al., 2000; Pellicciari et al., 2002; Mehlmann et al., 2009; Abel et al., 2010) and checked for identity and purity by 1H-NMR and liquid chromatography/mass…”
MethodCariello, M., Piccinin, E., García‐Irigoyen, O., Sabbà, C., & Moschetta, A. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.09.019 · Cited by 111
D’Amore, C., Leva, F. S. D., Sepe, V., Renga, B., Gaudio, C. D., D’Auria, M. V., Zampella, A., Fiorucci, S., & Limongelli, V. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401873d · Cited by 99
Self-citationHernandez, E. D., Zheng, L., Kim, Y., Fang, B., Liu, B., Valdez, R., Dietrich, W. F., Rucker, P. V., CHIANELLI, D., Schmeits, J., et al. (2019) · Hepatology Communications · doi:10.1002/hep4.1368 · Cited by 98
“(31) Tropifexor showed a halfmaximal effective concentration (EC50) in the subnanomolar range in several functional assays, including an assay measuring the interaction of FXR with steroid receptor coactivator 1 (SRC1; mean EC50, 0.20 nM) and a transcriptional activity assay measuring the promoter activity of a canoni…”
BackgroundInfluentialIntestinal Farnesoid X Receptor Signaling Modulates Metabolic Disease
Gonzalez, F. J., Jiang, C., Xie, C., & Patterson, A. D. (2017) · Digestive Diseases · doi:10.1159/000450908 · Cited by 95
Nicolaou, K. C., Evans, R. M., Roecker, A. J., Hughes, R., Downes, M., & Pfefferkorn, J. A. (2003) · Organic & Biomolecular Chemistry · doi:10.1039/b300525a · Cited by 95
The Concise Guide to PHARMACOLOGY 2013/14: Nuclear Hormone Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12448 · Cited by 95
Primary sclerosing cholangitis
Silveira, M. G., & Lindor, K. D. (2008) · Canadian Journal of Gastroenterology · doi:10.1155/2008/824168 · Cited by 93
Farnesoid X Receptor Protects against Kidney Injury in Uninephrectomized Obese Mice
Gai, Z., Gui, T., Hiller, C., & Kullak-Ublick, G. A. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.694323 · Cited by 93
“After 8 weeks of a HFD, half the obese mice were given OCA (25 mg/kg, mixed into the diet, Intercept Pharmaceuticals, NY, USA) to activate FXR (22).”
Farnesoid X receptor modulators 2014-present: a patent review
Sepe, V., Distrutti, E., Fiorucci, S., & Zampella, A. (2018) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2018.1459569 · Cited by 88
“of 6-ECDCA/obeticholic acid/Ocaliva (OCA in Figure 2)/INT-747 [29,30], with improved potency at FXR respected to the endogenous precursor, CDCA.”
BackgroundSelf-citationA Current Understanding of Bile Acids in Chronic Liver Disease
Farooqui, N., Elhence, A., & Shalimar, S. (2021) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2021.08.017 · Cited by 100
FXR: structures, biology, and drug development for NASH and fibrosis diseases
Tian, S., Chen, S., Pan, C., & Li, Y. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00849-4 · Cited by 102
Nuclear Receptor Control of Enterohepatic Circulation
Gonzalez, F. J. (2012) · Comprehensive physiology · doi:10.1002/cphy.c120007 · Cited by 110
Management of cholestatic disease in 2017
de Vries, E., & Beuers, U. (2017) · Liver International · doi:10.1111/liv.13306 · Cited by 90
Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery
Proschak, E., Heitel, P., Kalinowsky, L., & Merk, D. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01287 · Cited by 85
Nonacidic Farnesoid X Receptor Modulators
Flesch, D., Cheung, S.-Y., Schmidt, J., Gabler, M., Heitel, P., Kramer, J. S., Kaiser, A., Hartmann, M., Lindner, M., Lüddens-Dämgen, K., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00903 · Cited by 93
Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease
Abenavoli, L., Falalyeyeva, T. M., Boccuto, L., Tsyryuk, O., & Kobyliak, N. M. (2018) · Pharmaceuticals · doi:10.3390/ph11040104 · Cited by 96
“Obeticholic acid (OCA) is a first-in-class selective FXR agonist with anticholestatic and hepato-protective properties [27].”
BackgroundNi, X., & Wang, H. (2016) · PubMed · Cited by 113
FXR modulators for enterohepatic and metabolic diseases
Wang, H., He, Q., Wang, G., Xu, X., & Hao, H. (2018) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2018.1527906 · Cited by 87
“OCA not only promotes bile flow but also alleviates hepatocellular injury in rodent models of cholestasis induced by both LCA and estrogen [47,105].”
BackgroundDetermination of bile salt critical micellization concentration on the road to drug discovery
Natalini, B., Sardella, R., Gioiello, A., Ianni, F., Michele, A. D., & Marinozzi, M. (2013) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2013.06.029 · Cited by 88
Pydyn, N., Miękus, K., Jura, J., & Kotlinowski, J. (2020) · Pharmacological Reports · doi:10.1007/s43440-019-00020-1 · Cited by 96
Kriegermeier, A. A., & Green, R. R. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00149 · Cited by 97
Recent advances on FXR-targeting therapeutics
Panzitt, K., Zollner, G., Marschall, H., & Wagner, M. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111678 · Cited by 94
“cholestasis, OCA restored bile flow and improved cholestasis [4, 195].”
BackgroundHo, P. P., & Steinman, L. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1524890113 · Cited by 85
“The synthetic FXR ligand, 6-ECDCA, has ∼100-fold greater FXR agonistic activity than CDCA (17).”
BackgroundProgressive familial intrahepatic cholestasis: diagnosis, management, and treatment
Günaydın, M., & Cıl, A. T. B. (2018) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s137209 · Cited by 93
FXR silencing in human colon cancer by DNA methylation and KRAS signaling
Bailey, A. M., Zhan, L., Maru, D., Shureiqi, I., Pickering, C. R., Kiriakova, G., Izzo, J., He, N., Wei, C., Baladandayuthapani, V., et al. (2014) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00234.2013 · Cited by 85
Immunology of bile acids regulated receptors
Fiorucci, S., Marchianò, S., Urbani, G., Giorgio, C. D., Distrutti, E., Zampella, A., & Biagioli, M. (2024) · Progress in Lipid Research · doi:10.1016/j.plipres.2024.101291 · Cited by 92
Self-citationFesta, C., Renga, B., D’Amore, C., Sepe, V., Finamore, C., De Marino, S., Carino, A., Cipriani, S., Monti, M. C., Zampella, A., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501273r · Cited by 84
Self-citationVignozzi, L., Morelli, A., Filippi, S., Comeglio, P., Chavalmane, A. K., Marchetta, M., Toce, M., Yehiely-Cohen, R., Vannelli, G. B., Adorini, L., et al. (2011) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.02073.x · Cited by 83
Self-citationNew perspectives for the treatment of cholestasis: Lessons from basic science applied clinically
Boyer, J. L. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.12.001 · Cited by 95
“This knowledge has led to the development of several potent FXR ligands, particularly GW4064 [60] and 6-ethyl chenodeoxycholic acid (6-ECDCA), each of which has binding affinities for the ligand binding domain of FXR that are significantly greater than CDCA, the most potent endogenous FXR ligand [ 61 ].”
BackgroundBenz, M., Molla, M. R., Böser, A., Rosenfeld, A., & Levkin, P. A. (2019) · Nature Communications · doi:10.1038/s41467-019-10685-0 · Cited by 95
Goto, T., Itoh, M., Suganami, T., Kanai, S., Shirakawa, I., Sakai, T., Asakawa, M., Yoneyama, T., Kai, T., & Ogawa, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-26383-8 · Cited by 88
Attia, Y. M., Tawfiq, R. A., Ali, A. A., & Elmazar, M. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-12629-4 · Cited by 82
Bile acid receptors and nonalcoholic fatty liver disease
Yuan, L. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i28.2811 · Cited by 82
Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders
Fiorucci, S., Giorgio, C. D., & Distrutti, E. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_227 · Cited by 86
Self-citationObeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis
Kjærgaard, K., Frisch, K., Sørensen, M., Munk, O. L., Hofmann, A. F., Horsager, J., Schacht, A. C., Erickson, M., Shapiro, D., & Keiding, S. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.07.028 · Cited by 81
The interrelationship between bile acid and vitamin A homeostasis
Saeed, A., Hoekstra, M., Hoeke, M. O., Heegsma, J., & Faber, K. N. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2017.01.007 · Cited by 96
Bile Acid Uptake Transporters as Targets for Therapy
Slijepcevic, D., & van de Graaf, S. F. J. (2017) · Digestive Diseases · doi:10.1159/000450983 · Cited by 87
Role of bile acids in the regulation of the metabolic pathways
Taoka, H., Yokoyama, Y., Morimoto, K., Kitamura, N., Tanigaki, T., Takashina, Y., Tsubota, K., & Watanabe, M. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i13.260 · Cited by 80
Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression
Erice, O., Labiano, I., Arbelaiz, A., Santos‐Laso, Á., Muñoz-Garrido, P., Jiménez-Agüero, R., Olaizola, P., Caro‐Maldonado, A., Martín-Martín, N., Carracedo, A., et al. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.08.016 · Cited by 86
Structure-activity relationship of bile acids and bile acid analogs in regard to FXR activation
Fujino, T., Une, M., Imanaka, T., Inoue, K., & Nishimaki-Mogami, T. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m300215-jlr200 · Cited by 79
“This appears to be in contrast to ethyl substitution at the C-6� position of CDCA, which leads to great enhancement of FXR ligand potency ( 29 ).”
BackgroundRizzo, G., Renga, B., Antonelli, E., Passeri, D., Pellicciari, R., & Fiorucci, S. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.012104 · Cited by 91
“…previously that 6 -ethyl-chenodeoxycholic acid (6-ECDCA), a semisynthetic derivative of CDCA, is a potent and selective steroidal FXR agonist with an EC50 of 99 nM (Pellicciari et al., 2002) and protects against cholestasis and liver fibrosis when administered in vivo (Fiorucci et al., 2004, 2005).”
BackgroundSelf-citationNonsteroidal FXR Ligands: Current Status and Clinical Applications
Gege, C., Hambruch, E., Hambruch, N., Kinzel, O., & Kremoser, C. (2019) · Handbook of Experimental Pharmacology · doi:10.1007/164_2019_232 · Cited by 83
Morelli, A., Comeglio, P., Filippi, S., Sarchielli, E., Cellai, I., Vignozzi, L., Yehiely-Cohen, R., Maneschi, E., Gacci, M., Carini, M., et al. (2012) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2012.02.007 · Cited by 84
Self-citationRichter, H. G., Benson, G. M., Bleicher, K., Blum, D., Chaput, E., Clemann, N., Feng, S., Gardès, C., Grether, U., HARTMAN, P. G., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.12.123 · Cited by 79
Developments in bile salt based therapies: A critical overview
Donkers, J. M., Abbing, R. L. P. R., & van de Graaf, S. F. J. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.12.018 · Cited by 80
Bile Acid Signaling in Metabolic and Inflammatory Diseases and Drug Development
Li, T., & Chiang, J. Y. L. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.000978 · Cited by 90
Suppression of interleukin-6-induced C-reactive protein expression by FXR agonists
Zhang, S., Liu, Q., Wang, J., & Harnish, D. C. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.12.117 · Cited by 78
Stojancevic, M., Stankov, K., & Mikov, M. (2012) · Canadian Journal of Gastroenterology · doi:10.1155/2012/538452 · Cited by 75
“Consistent with this, Gadaleta et al (8) also showed that administration of the FXR agonist INT-747 alleviated intestinal inflammation in two models of murine colitis.”
BackgroundDas, A., Fernández-Zapico, M. E., Cao, S., Yao, J. Z., Fiorucci, S., Hebbel, R. P., Urrutia, R. A., & Shah, V. H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m607720200 · Cited by 83
Self-citationFXR-dependent Rubicon induction impairs autophagy in models of human cholestasis
Panzitt, K., Jungwirth, E., Krones, E., Lee, J. M., Pollheimer, M., Thallinger, G. G., Kolb-Lenz, D., Xiao, R., Thorell, A., Trauner, M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.01.014 · Cited by 75
Recent Progress on Bile Acid Receptor Modulators for Treatment of Metabolic Diseases
Xu, Y. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00342 · Cited by 77
Novel and emerging therapies for cholestatic liver diseases
Goldstein, J., & Levy, C. (2018) · Liver International · doi:10.1111/liv.13880 · Cited by 77
Regulation of bile acid receptor activity
Wan, Y. Y., & Sheng, L. (2018) · Liver Research · doi:10.1016/j.livres.2018.09.008 · Cited by 83
Drug Therapies for Chronic Cholestatic Liver Diseases
Wagner, M., & Fickert, P. (2019) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021059 · Cited by 78
Recent Advances in the Medicinal Chemistry of Farnesoid X Receptor
Fang, Y., Hegazy, L., Finck, B. N., & Elgendy, B. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01017 · Cited by 75
Synthetic Approaches to New Drugs Approved During 2016
Flick, A. C., Ding, H. X., Leverett, C. A., Fink, S. J., & O’Donnell, C. J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00260 · Cited by 72
Immunomodulatory functions of FXR
Fiorucci, S., Zampella, A., Ricci, P., Distrutti, E., & Biagioli, M. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111650 · Cited by 70
Self-citationGrienke, U., Mihaly‐Bison, J., Schuster, D., Afonyushkin, T., Binder, M., Guan, S., Cheng, C., Wolber, G., Stuppner, H., Guo, D., et al. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.09.039 · Cited by 71
The Farnesoid X Receptor (FXR) as Modulator of Bile Acid Metabolism
Kuipers, F., Claudel, T., Sturm, E., & Staels, B. (2004) · Reviews in Endocrine and Metabolic Disorders · doi:10.1023/b:remd.0000045103.00467.9a · Cited by 75
“The lithocholic acid-induced cholestasis model is another model of intrahepatic cholestasis in which the chenodeoxycholic acid derivate 6-ECDCA, a high affinity FXR ligand, was tested [66].”
Structure-guided discovery of bile acid derivatives for treating liver diseases without causing itch
Yang, J. J. J., Zhao, T., Fan, J., Zou, H., Lan, G., Guo, F., Shi, Y., Ke, H., Yu, H., Yue, Z., et al. (2024) · Cell · doi:10.1016/j.cell.2024.10.001 · Cited by 80
“21 31 Notably, pruritus is by far the most common OCA-associated adverse effect, and it is dose-dependent, sometimes necessitating discontinuation of the trial for certain patients.”
Nonalcoholic Steatohepatitis (NASH) and Hepatic Fibrosis: Emerging Therapies
Wattacheril, J. J., Issa, D., & Sanyal, A. J. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052545 · Cited by 72
Meng, Q., Duan, X., Wang, C., Liu, Z., Sun, P., Huo, X., Sun, H., Peng, J., & Liu, K. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.119 · Cited by 72
Nakada, E. M., Bhakta, N. R., Korwin-Mihavics, B. R., Kumar, A., Chamberlain, N., Bruno, S. R., Chapman, D. G., Hoffman, S. M., Daphtary, N., Aliyeva, M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.98101 · Cited by 73
Sepe, V., Bifulco, G., Renga, B., D’Amore, C., Fiorucci, S., & Zampella, A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101336m · Cited by 67
Self-citationRole of farnesoid X receptor in inflammation and resolution
Shaik, F. B., Prasad, D. V. R., & Narala, V. R. (2014) · Inflammation Research · doi:10.1007/s00011-014-0780-y · Cited by 72
“The most widely used FXR ligand is GW4064, but its cell-toxic effect and uncertain bioavailability restricted its further use and 6ECDCA derived from natural FXR ligand CDCA, has become an alternative agonist for FXR [18– 21].”
BackgroundFXR activation normalizes insulin sensitivity in visceral preadipocytes of a rabbit model of MetS
Maneschi, E., Vignozzi, L., Morelli, A., Mello, T., Filippi, S., Cellai, I., Comeglio, P., Sarchielli, E., Calcagno, A., Mazzanti, B., et al. (2013) · Journal of Endocrinology · doi:10.1530/joe-13-0109 · Cited by 68
“Structure, potency, and selectivity toward other nuclear hormone receptors have been described previously (Pellicciari et al. 2002, Rizzo et al. 2010).”
BackgroundMethodSelf-citation
Metadata
- Authors
- Pellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M.
- Affiliations
- University of Perugia (IT)
- Corresponding author
- Pellicciari, Roberto
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2002-07-20
- Volume
- 45
- Issue
- 17
- Pages
- 3569-3572
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2049515100
- Cited by
- 743
- References
- 15
- Citations by year
- 2026: 20 · 2025: 33 · 2024: 32 · 2023: 33 · 2022: 46 · 2021: 47 · 2020: 54 · 2019: 46 · 2018: 52 · 2017: 60 · 2016: 49 · 2015: 38 · 2014: 35 · 2013: 27 · 2012: 31
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- farnesoid X receptor agonist, cholestasis, bile acid synthesis inhibition, receptor selectivity
- MeSH terms
- Receptor, Farnesoid X-Activated, Animals, Anticholesteremic Agents, Cell Line, Chenodeoxycholic Acid, Cholestasis, DNA-Binding Proteins, Humans, Ligands, Liver, Structure-Activity Relationship, Transcription Factors, Rats, Wistar, Receptors, Cytoplasmic and Nuclear, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.